TGTX Stock Analysis Today
Updated Nov 12, 2026 · trends, key levels, insider activity and news
Is TGTX bullish or bearish today?
Daily trend: Uptrend (starting) — turns down below $45.37
SEPT signal: Distribution · Strong Bullish
Research grade: B+ · fair value $37.52 (+16.0%)
TGTX trend by timeframe
| Daily | Uptrend (starting) |
|---|---|
| 4 hour | Strong Bullish |
| 1 hour | Strong Bullish |
| 15 min | Bullish |
| 5 min | Strong Bullish |
Trends are calculated from price structure and update during market hours.
TGTX support and resistance levels
Resistance (above)
—
Support (below)
$63.601 touches
$58.924 touches
$54.6015 touches
Upside zones: $60.32 / $62.04 / $63.77
See all levels on the live chart →Insider and institutional activity
Insiders
Neutral30-day buys / sells
0 / 030-day net
—Hedge fund holders
356Latest TGTX news and filings
- AnalystBenzinga
Evercore ISI keeps Outperform rating on TG Therapeutics, cuts target to $71
Evercore ISI Group kept its Outperform rating on TG Therapeutics while lowering its price target to $71. The change reflects the firm's updated view on the stock.
- EarningsBenzinga
TG Therapeutics holds Q3 2026 earnings call
TG Therapeutics discussed its third-quarter 2026 results during its earnings call. The headline gives no figures or details from the quarter.
- EarningsFiscal.ai
TG Therapeutics lifts FY guidance after Q3 2026 report
The company posted its quarterly numbers for the period ending in 2026 and told the market its full-year sales outlook is now higher than before.
- SEC FilingSECTg Therapeutics, Inc. filed a report on a major company event (Form 8-K)
Form 8-K tells shareholders about important events such as deals, leadership changes or results.
- EarningsBenzinga
TG Therapeutics posts $0.35 quarterly profit, revenue of $259.936M
The biopharma company's third-quarter profit of $0.35 per share came in above the $0.34 consensus. Revenue of $259.936 million also topped the $245.475 million estimate.
- GuidanceBenzinga
TG Therapeutics lifts FY2026 sales guidance to $1.000B from $950.000M
TG Therapeutics now expects fiscal 2026 sales of $1.000 billion, up from its earlier $950.000 million outlook. The new figure sits above the $960.306 million consensus estimate.
Live TGTX chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Why did TGTX stock move on Nov 9, 2026?
Nov 9, 2026: TG Therapeutics reported third-quarter 2026 results that beat expectations, posting earnings of $0.35 per share versus the $0.34 consensus and revenue of $259.936 million against the $245.475 million estimate. The company also raised its full-year 2026 sales guidance to $1.000 billion from $950.000 million, topping the $960.306 million consensus.
Is TGTX bullish or bearish today?
TGTX daily trend: Uptrend (starting) — turns down below $45.365. SEPT signal: Distribution (Strong Bullish). Updated Nov 12, 2026.
What is TGTX's trend on each timeframe?
Daily: Uptrend (starting); 4 hour: Strong Bullish; 1 hour: Strong Bullish; 15 min: Bullish; 5 min: Strong Bullish.
What are TGTX support and resistance levels?
Support: $63.60, $58.92, $54.60. Last price $65.76.
Are insiders buying or selling TGTX?
Insider signal: Neutral. Last 30 days: 0 buys, 0 sells. 356 hedge funds hold TGTX.
What is the latest news on TGTX?
Nov 10, 2026: Evercore ISI keeps Outperform rating on TG Therapeutics, cuts target to $71 · Nov 9, 2026: TG Therapeutics holds Q3 2026 earnings call · Nov 9, 2026: TG Therapeutics lifts FY guidance after Q3 2026 report